Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Aurinia Pharmaceuticals Inc. < Previous 1 2 3 Next > Aurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark Office January 24, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-year 2022 Net Revenue Results January 06, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals to Present at Upcoming 41st Annual J.P. Morgan Healthcare Conference January 04, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 03, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun Pharmaceuticals January 03, 2023 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 05, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis November 30, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Reports Third Quarter and Nine Months 2022 Financial and Operational Results November 03, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals to Release Third Quarter 2022 Financial and Operational Results on November 3, 2022 October 28, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Announces Presentations at American Society of Nephrology (ASN) Kidney Week 2022 October 27, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 03, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Announces Presentations at American College of Rheumatology (ACR) Convergence 2022 September 20, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Announces European Commission Approval of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis September 19, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results August 04, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 01, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review July 26, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022 July 25, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe July 22, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance July 14, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 06, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations June 03, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress May 20, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress May 16, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Reports First Quarter 2022 Financial and Operational Results May 10, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022 May 06, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022 May 02, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis April 19, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings April 04, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates February 28, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021 February 09, 2022 From Aurinia Pharmaceuticals Inc. Via Business Wire Tickers AUPH < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.